Heart failure with preserved ejection fraction in Asia

on behalf of the ASIAN-HF Investigators

doi:10.1002/ejhf.1227

Heart failure with preserved ejection fraction in Asia

on behalf of the ASIAN-HF Investigators

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Article › peer-review

77 Scopus citations

Abstract

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem. Unfortunately, little is known about HFpEF across Asia.

METHODS AND RESULTS: We prospectively studied clinical characteristics, echocardiographic parameters and outcomes in 1204 patients with HFpEF (left ventricular ejection fraction ≥50%) from 11 Asian regions, grouped as Northeast Asia (Hong Kong, Taiwan, China, Japan, Korea, n = 543), South Asia (India, n = 252), and Southeast Asia (Malaysia, Thailand, Singapore, Indonesia, Philippines, n = 409). Mean age was 68 ±12 years (37% were < 65 years) and 50% were women. Seventy per cent of patients had ≥2 co-morbidities, most commonly hypertension (71%), followed by anaemia (57%), chronic kidney disease (50%), diabetes (45%), coronary artery disease (29%), atrial fibrillation (29%) and obesity (26%). Southeast Asian patients had the highest prevalence of all co-morbidities except atrial fibrillation, South Asians had the lowest prevalence of all co-morbidities except anaemia and obesity, and Northeast Asians had more atrial fibrillation. Left ventricular hypertrophy and concentric remodelling were most prominent among Southeast and South Asians, respectively (P < 0.001). Overall, 12.1% of patients died or were hospitalized for heart failure within 1 year. Southeast Asians were at higher risk for adverse outcomes, independent of co-morbidity burden and cardiac geometry.

CONCLUSION: These first prospective multinational data from Asia show that HFpEF affects relatively young patients with a high burden of co-morbidities. Regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia have important implications for public health measures and global HFpEF trial design.

Original language	English (US)
Pages (from-to)	23-36
Number of pages	14
Journal	European Journal of Heart Failure
Volume	21
Issue number	1
DOIs	https://doi.org/10.1002/ejhf.1227
State	Published - Jan 2019

Bibliographical note

Funding Information:
The ASIAN-HF study is supported by grants from Boston Scientific Investigator Sponsored Research Program, National Medical Research Council of Singapore, A*STAR Biomedical Research Council ATTRaCT program, and Bayer. Conflict of interest: C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Thermofisher, Medtronic, and Vifor Pharma; and has consulted for Bayer, Novartis, Takeda, Merck, AstraZeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Roche, and Amgen. The other authors have nothing to disclose.

Keywords

Asia
Co-morbidities
Echocardiography
Heart failure with preserved ejection fraction
Public Health
Prevalence
Prospective Studies
Follow-Up Studies
Ventricular Function, Left
Comorbidity
Humans
Middle Aged
Male
Stroke Volume/physiology
Heart Failure/diagnosis
Asia/epidemiology
Female
Aged

PubMed: MeSH publication types

Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1002/ejhf.1227

Find It

Find It at U of M Libraries

Cite this

@article{8b38b7c266fa4922a1d89ac41336e1eb,

title = "Heart failure with preserved ejection fraction in Asia",

abstract = "BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem. Unfortunately, little is known about HFpEF across Asia.METHODS AND RESULTS: We prospectively studied clinical characteristics, echocardiographic parameters and outcomes in 1204 patients with HFpEF (left ventricular ejection fraction ≥50%) from 11 Asian regions, grouped as Northeast Asia (Hong Kong, Taiwan, China, Japan, Korea, n = 543), South Asia (India, n = 252), and Southeast Asia (Malaysia, Thailand, Singapore, Indonesia, Philippines, n = 409). Mean age was 68 ±12 years (37% were < 65 years) and 50% were women. Seventy per cent of patients had ≥2 co-morbidities, most commonly hypertension (71%), followed by anaemia (57%), chronic kidney disease (50%), diabetes (45%), coronary artery disease (29%), atrial fibrillation (29%) and obesity (26%). Southeast Asian patients had the highest prevalence of all co-morbidities except atrial fibrillation, South Asians had the lowest prevalence of all co-morbidities except anaemia and obesity, and Northeast Asians had more atrial fibrillation. Left ventricular hypertrophy and concentric remodelling were most prominent among Southeast and South Asians, respectively (P < 0.001). Overall, 12.1% of patients died or were hospitalized for heart failure within 1 year. Southeast Asians were at higher risk for adverse outcomes, independent of co-morbidity burden and cardiac geometry.CONCLUSION: These first prospective multinational data from Asia show that HFpEF affects relatively young patients with a high burden of co-morbidities. Regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia have important implications for public health measures and global HFpEF trial design.",

keywords = "Asia, Co-morbidities, Echocardiography, Heart failure with preserved ejection fraction, Public Health, Prevalence, Prospective Studies, Follow-Up Studies, Ventricular Function, Left, Comorbidity, Humans, Middle Aged, Male, Stroke Volume/physiology, Heart Failure/diagnosis, Asia/epidemiology, Female, Aged",

author = "{on behalf of the ASIAN-HF Investigators} and Jasper Tromp and Teng, {Tiew Hwa} and Tay, {Wan Ting} and Hung, {Chung Lieh} and Calambur Narasimhan and Wataru Shimizu and Park, {Sang Weon} and Liew, {Houng Bang} and Tachapong Ngarmukos and Reyes, {Eugene B.} and Siswanto, {Bambang B.} and Yu, {Cheuk Man} and Shu Zhang and Jonathan Yap and Michael MacDonald and Ling, {Lieng Hsi} and Kirsten Leineweber and Richards, {A. Mark} and Zile, {Michael R.} and Anand, {Inder S.} and Lam, {Carolyn S.P.}",

note = "Funding Information: The ASIAN-HF study is supported by grants from Boston Scientific Investigator Sponsored Research Program, National Medical Research Council of Singapore, A*STAR Biomedical Research Council ATTRaCT program, and Bayer. Conflict of interest: C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Thermofisher, Medtronic, and Vifor Pharma; and has consulted for Bayer, Novartis, Takeda, Merck, AstraZeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Roche, and Amgen. The other authors have nothing to disclose.",

year = "2019",

month = jan,

doi = "10.1002/ejhf.1227",

language = "English (US)",

volume = "21",

pages = "23--36",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Heart failure with preserved ejection fraction in Asia

AU - on behalf of the ASIAN-HF Investigators

AU - Tromp, Jasper

AU - Teng, Tiew Hwa

AU - Tay, Wan Ting

AU - Hung, Chung Lieh

AU - Narasimhan, Calambur

AU - Shimizu, Wataru

AU - Park, Sang Weon

AU - Liew, Houng Bang

AU - Ngarmukos, Tachapong

AU - Reyes, Eugene B.

AU - Siswanto, Bambang B.

AU - Yu, Cheuk Man

AU - Zhang, Shu

AU - Yap, Jonathan

AU - MacDonald, Michael

AU - Ling, Lieng Hsi

AU - Leineweber, Kirsten

AU - Richards, A. Mark

AU - Zile, Michael R.

AU - Anand, Inder S.

AU - Lam, Carolyn S.P.

N1 - Funding Information: The ASIAN-HF study is supported by grants from Boston Scientific Investigator Sponsored Research Program, National Medical Research Council of Singapore, A*STAR Biomedical Research Council ATTRaCT program, and Bayer. Conflict of interest: C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Thermofisher, Medtronic, and Vifor Pharma; and has consulted for Bayer, Novartis, Takeda, Merck, AstraZeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Roche, and Amgen. The other authors have nothing to disclose.

PY - 2019/1

Y1 - 2019/1

N2 - BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem. Unfortunately, little is known about HFpEF across Asia.METHODS AND RESULTS: We prospectively studied clinical characteristics, echocardiographic parameters and outcomes in 1204 patients with HFpEF (left ventricular ejection fraction ≥50%) from 11 Asian regions, grouped as Northeast Asia (Hong Kong, Taiwan, China, Japan, Korea, n = 543), South Asia (India, n = 252), and Southeast Asia (Malaysia, Thailand, Singapore, Indonesia, Philippines, n = 409). Mean age was 68 ±12 years (37% were < 65 years) and 50% were women. Seventy per cent of patients had ≥2 co-morbidities, most commonly hypertension (71%), followed by anaemia (57%), chronic kidney disease (50%), diabetes (45%), coronary artery disease (29%), atrial fibrillation (29%) and obesity (26%). Southeast Asian patients had the highest prevalence of all co-morbidities except atrial fibrillation, South Asians had the lowest prevalence of all co-morbidities except anaemia and obesity, and Northeast Asians had more atrial fibrillation. Left ventricular hypertrophy and concentric remodelling were most prominent among Southeast and South Asians, respectively (P < 0.001). Overall, 12.1% of patients died or were hospitalized for heart failure within 1 year. Southeast Asians were at higher risk for adverse outcomes, independent of co-morbidity burden and cardiac geometry.CONCLUSION: These first prospective multinational data from Asia show that HFpEF affects relatively young patients with a high burden of co-morbidities. Regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia have important implications for public health measures and global HFpEF trial design.

AB - BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem. Unfortunately, little is known about HFpEF across Asia.METHODS AND RESULTS: We prospectively studied clinical characteristics, echocardiographic parameters and outcomes in 1204 patients with HFpEF (left ventricular ejection fraction ≥50%) from 11 Asian regions, grouped as Northeast Asia (Hong Kong, Taiwan, China, Japan, Korea, n = 543), South Asia (India, n = 252), and Southeast Asia (Malaysia, Thailand, Singapore, Indonesia, Philippines, n = 409). Mean age was 68 ±12 years (37% were < 65 years) and 50% were women. Seventy per cent of patients had ≥2 co-morbidities, most commonly hypertension (71%), followed by anaemia (57%), chronic kidney disease (50%), diabetes (45%), coronary artery disease (29%), atrial fibrillation (29%) and obesity (26%). Southeast Asian patients had the highest prevalence of all co-morbidities except atrial fibrillation, South Asians had the lowest prevalence of all co-morbidities except anaemia and obesity, and Northeast Asians had more atrial fibrillation. Left ventricular hypertrophy and concentric remodelling were most prominent among Southeast and South Asians, respectively (P < 0.001). Overall, 12.1% of patients died or were hospitalized for heart failure within 1 year. Southeast Asians were at higher risk for adverse outcomes, independent of co-morbidity burden and cardiac geometry.CONCLUSION: These first prospective multinational data from Asia show that HFpEF affects relatively young patients with a high burden of co-morbidities. Regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia have important implications for public health measures and global HFpEF trial design.

KW - Asia

KW - Co-morbidities

KW - Echocardiography

KW - Heart failure with preserved ejection fraction

KW - Public Health

KW - Prevalence

KW - Prospective Studies

KW - Follow-Up Studies

KW - Ventricular Function, Left

KW - Comorbidity

KW - Humans

KW - Middle Aged

KW - Male

KW - Stroke Volume/physiology

KW - Heart Failure/diagnosis

KW - Asia/epidemiology

KW - Female

KW - Aged

UR - http://www.scopus.com/inward/record.url?scp=85052486984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052486984&partnerID=8YFLogxK

U2 - 10.1002/ejhf.1227

DO - 10.1002/ejhf.1227

M3 - Article

C2 - 30113120

AN - SCOPUS:85052486984

VL - 21

SP - 23

EP - 36

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 1

ER -

Heart failure with preserved ejection fraction in Asia

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this